Research ArticleOriginal Research

Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic

Kelly Shum, Amber Solivan, Parham Parto, Nichole Polin and Eiman Jahangir
Ochsner Journal September 2016, 16 (3) 217-224;

REFERENCES

  1. ↵
    SEER stat fact sheets: female breast cancer. National Cancer Institute: Surveillance, Epidemiology, and End Results Program Web site. http://seer.cancer.gov/statfacts/html/breast.html. Published 2014. Accessed July 19, 2016.
  2. ↵
    1. Patnaik JL,
    2. Byers T,
    3. DiGuiseppi C,
    4. Dabelea D,
    5. Denberg TD.
    Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011 6 20; 13 3: R64 doi:10.1186/bcr2901. pmid:21689398
    OpenUrlCrossRefPubMed
  3. ↵
    1. Slamon DJ,
    2. Leyland-Jones B,
    3. Shak S,
    4. et al.
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 3 15; 344 11: 783- 792. pmid:11248153
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Steinherz LJ,
    2. Steinherz PG,
    3. Tan CT,
    4. Heller G,
    5. Murphy ML.
    Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 9 25; 266 12: 1672- 1677. pmid:1886191
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Cardinale D,
    2. Colombo A,
    3. Bacchiani G,
    4. et al.
    Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 6 2; 131 22: 1981- 1988. doi: 10.1161/CIRCULATIONAHA.114.013777. pmid:25948538
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Feijen EA,
    2. Leisenring WM,
    3. Stratton KL,
    4. et al.
    Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol. 2015 11 10; 33 32: 3774- 3780. doi: 10.1200/JCO.2015.61.5187. pmid:26304888
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Felker GM,
    2. Thompson RE,
    3. Hare JM,
    4. et al.
    Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 4 13; 342 15: 1077- 1084. pmid:10760308
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Cardinale D,
    2. Colombo A,
    3. Lamantia G,
    4. et al.
    Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 1 19; 55 3: 213- 220. doi: 10.1016/j.jacc.2009.03.095. pmid:20117401
    OpenUrlFREE Full Text
  9. ↵
    1. Taunk NK,
    2. Haffty BG,
    3. Kostis JB,
    4. Goyal S.
    Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015 2 18; 5: 39 doi:10.3389/fonc.2015.00039. pmid:25741474
    OpenUrlCrossRefPubMed
    1. Mandraffino G,
    2. Dalbeni A,
    3. Paunovic N,
    4. Mormina EM,
    5. Imbalzano E.
    Radiation-induced heart and vessel atherosclerosis disease. Int J Cardiol. 2014 3 15; 172 2: 505- 506. doi: 10.1016/j.ijcard.2014.01.059. pmid:24485624
    OpenUrlCrossRefPubMed
  11. ↵
    1. Mousavi N,
    2. Nohria A.
    Radiation-induced cardiovascular disease. Curr Treat Options Cardiovasc Med. 2013 10; 15 5: 507- 517. doi: 10.1007/s11936-013-0259-0. pmid:24092234
    OpenUrlCrossRefPubMed
  12. ↵
    1. Goff DC Jr.,
    2. Lloyd-Jones DM,
    3. Bennett G,
    4. et al.
    American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1; 63 25 Pt B: 2935- 2959. doi: 10.1016/j.jacc.2013.11.005. pmid:24239921
    OpenUrlCrossRefPubMed
  13. ↵
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III ) Final Report. Circulation. 2002 12 17; 106 25: 3143- 3421. pmid:12485966
    OpenUrlFREE Full Text
  14. ↵
    1. Cardinale D,
    2. Colombo A,
    3. Lamantia G,
    4. et al.
    Cardio-oncology: a new medical issue. Ecancermedicalscience. 2008; 2: 126 doi: 10.3332/ecancer.2008.126. pmid:22275992
    OpenUrlCrossRefPubMed
  15. ↵
    1. Albini A,
    2. Pennesi G,
    3. Donatelli F,
    4. Cammarota R,
    5. De Flora S,
    6. Noonan DM.
    Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010 1 6; 102 1: 14- 25. doi: 10.1093/jnci/djp440. pmid:20007921
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. et al.
    American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24; 129 25 Suppl 2: S1- 45. doi: 10.1161/01.cir.0000437738.63853.7a. pmid:24222016
    OpenUrlCrossRefPubMed
  17. ↵
    1. D'Agostino RB Sr.,
    2. Vasan RS,
    3. Pencina MJ,
    4. et al.
    General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008 2 12; 117 6: 743- 753. doi: 10.1161/CIRCULATIONAHA.107.699579. pmid:18212285
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Nelson ER,
    2. Chang CY,
    3. McDonnell DP.
    Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014 12; 25 12: 649- 655. doi: 10.1016/j.tem.2014.10.001. pmid:25458418
    OpenUrlCrossRefPubMed
  19. ↵
    1. Nelson ER,
    2. Wardell SE,
    3. Jasper JS,
    4. et al.
    27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013 11 29; 342 6162: 1094- 1098. doi: 10.1126/science.1241908. pmid:24288332
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Chan KK,
    2. Oza AM,
    3. Siu LL.
    The statins as anticancer agents. Clin Cancer Res. 2003 1; 9 1: 10- 19. pmid:12538446
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Wong WW,
    2. Dimitroulakos J,
    3. Minden MD,
    4. Penn LZ.
    HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002 4; 16 4: 508- 519. pmid:11960327
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Torres CG,
    2. Olivares A,
    3. Stoore C.
    Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells. Oncol Rep. 2015 5; 33 5: 2235- 2244. doi: 10.3892/or.2015.3850. pmid:25778435
    OpenUrlCrossRefPubMed
  23. ↵
    1. Myers CE,
    2. McGuire WP,
    3. Liss RH,
    4. Ifrim I,
    5. Grotzinger K,
    6. Young RC.
    Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 7 8; 197 4299: 165- 167. pmid:877547
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Bowles EJ,
    2. Wellman R,
    3. Feigelson HS,
    4. et al.
    Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 9 5; 104 17: 1293- 1305. doi: 10.1093/jnci/djs317. pmid:22949432
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Riad A,
    2. Bien S,
    3. Westermann D,
    4. et al.
    Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res. 2009 1 15; 69 2: 695- 699. doi: 10.1158/0008-5472.CAN-08-3076. pmid:19147586
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Chaosuwannakit N,
    2. D'Agostino R Jr.,
    3. Hamilton CA,
    4. et al.
    Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010 1 1; 28 1: 166- 172. doi: 10.1200/JCO.2009.23.8527. pmid:19901105
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Seicean S,
    2. Seicean A,
    3. Plana JC,
    4. Budd GT,
    5. Marwick TH.
    Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012 12 11; 60 23: 2384- 2390. doi: 10.1016/j.jacc.2012.07.067. pmid:23141499
    OpenUrlFREE Full Text
  28. ↵
    1. Ewer MS,
    2. Lippman SM.
    Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005 5 1; 23 13: 2900- 2902. pmid:15860848
    OpenUrlFREE Full Text
  29. ↵
    1. Kökoğlu E,
    2. Karaarslan I,
    3. Karaarslan HM,
    4. Baloğlu H.
    Alterations of serum lipids and lipoproteins in breast cancer. Cancer Lett. 1994 7 29; 82 2: 175- 178. pmid:8050088
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Alexopoulos CG,
    2. Blatsios B,
    3. Avgerinos A.
    Serum lipids and lipoprotein disorders in cancer patients. Cancer. 1987 12 15; 60 12: 3065- 3070. pmid:3677028
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords